Oregon Attorney General Dan Rayfield has joined federal regulators and 12 other states in a lawsuit seeking to block a $3.5 billion acquisition that would combine two of the nation’s largest veterinary supply distributors, raising concerns about competition, wholesale pricing and the cost of animal medical care.
The Oregon Department of Justice announced its participation Monday, November 16, following a November 13 complaint filed by the Federal Trade Commission in the U.S. District Court for the Southern District of New York. The lawsuit challenges Covetrus Inc.’s proposed acquisition of MWI Veterinary Supply, a subsidiary of pharmaceutical distributor Cencora Inc., alleging the transaction would substantially reduce competition in the veterinary supply industry.
Covetrus and MWI distribute prescription medications, vaccines, surgical equipment, diagnostic products and other medical supplies to veterinary clinics, animal hospitals and corporate veterinary networks nationwide, including practices throughout Oregon.
“Oregonians love our pets. When your dog or cat gets sick, you shouldn’t have to wonder if you can afford to get them care,” Rayfield stated in the Oregon Department of Justice announcement.
Regulators contend that eliminating competition between the companies could weaken the ability of veterinary practices to negotiate wholesale prices, purchasing rebates and supply contracts, potentially increasing operating expenses that could be passed along to pet owners.
The proposed acquisition would transfer MWI from Cencora to Covetrus, which is owned by private equity firms Clayton, Dubilier & Rice and TPG. Both firms are named in the federal litigation.
The complaint identifies two markets where regulators allege the merger would substantially reduce competition: distribution to individual veterinary clinics and supply services for large corporate veterinary accounts.
Federal investigators documented pricing competition between Covetrus and MWI, including instances in which MWI’s discounts prompted Covetrus to introduce competing rebates through its VetSuite program. The complaint also identifies Vetcove, an online purchasing platform that allows veterinary practices to compare supplier prices and product availability, as a factor increasing competition among distributors.
Covetrus, MWI and Patterson Veterinary are among the industry’s three principal national distributors. Their extensive warehousing operations and delivery networks supply veterinary facilities with medications and equipment, often under negotiated purchasing agreements.
Although regional distributors, manufacturers and specialty suppliers also serve veterinary practices, regulators argue that those businesses lack the capacity to replace the competition that would disappear if Covetrus acquired MWI.
The legal challenge comes amid substantial increases in veterinary care expenses. Figures cited by the California Department of Justice indicate that veterinary prices have risen approximately 60 percent nationally since 2014, including 5.7 percent between August 2025 and August 2026. Those increases preceded the proposed acquisition and are not attributed to the transaction.
Independent veterinary practices throughout Oregon, including clinics serving Grants Pass, Medford, Roseburg, Klamath Falls and surrounding rural communities, rely on national distribution networks for medications, vaccines and medical supplies.
Smaller practices generally purchase lower volumes than corporate veterinary networks, making competitive wholesale pricing and negotiated discounts important to their operating budgets. Regulators allege the merger could increase those costs, although no specific increase in Oregon veterinary bills has been established.
The lawsuit also raises concerns about product availability and delivery reliability. Veterinary clinics frequently use multiple distributors to obtain essential medications and supplies during inventory shortages or shipping disruptions. Regulators contend that consolidation could reduce those alternatives and weaken incentives to maintain competitive service standards.
MWI also distributes animal health products to livestock producers and large-animal veterinary practices, connecting its operations to agricultural communities throughout Oregon. The federal complaint, however, specifically addresses competition in veterinary clinic distribution and large corporate veterinary accounts.
Covetrus disputes the government’s allegations, arguing that regulators have underestimated competition from manufacturers, regional distributors and online purchasing platforms.
The company maintains that the acquisition would improve distribution efficiency, product availability and access to veterinary technology. It has indicated that it intends to defend the transaction in federal court.
The FTC authorized the lawsuit by a 2-0 vote, seeking a permanent injunction under Section 7 of the Clayton Act, which prohibits acquisitions that may substantially lessen competition or tend to create a monopoly.
Oregon joined Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio and Texas in the federal challenge.
The case remains pending in the Southern District of New York. No court has determined that the proposed acquisition violates federal antitrust law.
A ruling will determine whether Covetrus can complete its $3.5 billion purchase of MWI, with the outcome potentially affecting purchasing arrangements and distribution services for veterinary practices throughout Oregon and nationwide.

